Chicago Atlantic Taps NAV Loan to Fund Cannabis Growth Spree

Chicago Atlantic Real Estate Finance just closed a $300 million credit facility backed by the net asset value of its existing loan portfolio — a financing structure more common in private equity than in publicly traded lending vehicles. The deal, arranged with funds managed by Ares Management, gives the business development company dry powder to keep writing checks in a sector where capital remains scarce and federal reform remains theoretical.

The move is a bet that cannabis real estate credit — loans secured by cultivation facilities, dispensaries, and processing plants — can generate double-digit returns even as the industry waits for Congress to act. Chicago Atlantic has built an $800 million portfolio lending to state-legal cannabis operators who can't access traditional bank financing. Now it's leveraging that portfolio to fund the next wave of deals.

NAV financing isn't new. Private equity funds have used it for years to pull forward liquidity without selling assets. But for a BDC — a publicly traded vehicle designed to lend to small and mid-sized companies — it's an unconventional step. It signals two things: confidence that the underlying loans will perform, and urgency to deploy capital before the market shifts.

Chicago Atlantic's announcement comes as cannabis operators face a liquidity crunch. Public markets for cannabis stocks have cratered. Venture capital has mostly exited the sector. And despite talk of federal rescheduling or banking reform, the Safe Banking Act remains stalled. That leaves borrowers dependent on specialty lenders like Chicago Atlantic — and those lenders dependent on non-bank capital sources.

A net asset value facility is a credit line secured by the value of a fund's existing assets rather than by the cash flows of a single borrower. In this case, Ares is lending to Chicago Atlantic against the appraised value of its cannabis real estate loan book. If Chicago Atlantic's loans perform, the facility gets repaid. If they don't, Ares has a claim on the collateral.

The structure is common in private credit, where closed-end funds use NAV lines to smooth capital deployment between fundraising cycles. It's less common among BDCs, which already have access to public equity markets and can issue debt at the corporate level. That Chicago Atlantic chose this route suggests either that traditional corporate debt was too expensive or that management wanted leverage that didn't require immediate equity dilution.

The $300 million facility gives Chicago Atlantic roughly 37% more lending capacity relative to its current assets under management. That's significant firepower in a market where deal flow has slowed but hasn't stopped. The company didn't disclose the interest rate or advance rate on the facility, but NAV loans in private credit typically lend 50-70% of appraised portfolio value at spreads of 3-5% over SOFR.

What makes this financing slightly riskier than traditional corporate debt is that it's mark-to-market. If the appraised value of Chicago Atlantic's loan portfolio declines — say, because cannabis real estate valuations fall or a cluster of loans default — the advance rate resets and the company may need to repay a portion of the facility. That's a tail risk in a sector where property values are still being established.

Chicago Atlantic's business model is straightforward: lend to cannabis operators at interest rates that compensate for federal illegality, state-by-state regulatory fragmentation, and the lack of bankruptcy protections. The company's portfolio consists primarily of senior secured loans backed by cultivation facilities and dispensary properties. Average loan size is $10-15 million. Average yield is in the low double digits.

The value proposition for borrowers is equally clear: they can't get a loan from Wells Fargo. Despite state-level legalization in 38 states, cannabis remains a Schedule I controlled substance under federal law. That means federally regulated banks won't touch the sector, leaving operators dependent on specialty lenders, private credit funds, and a small cohort of state-chartered banks.

Chicago Atlantic has positioned itself as the real estate-focused player in this market. Unlike revenue-based lenders or equity investors, the company underwrites based on hard asset value — the building, the HVAC, the grow lights — rather than the business's ability to sell product. That makes the loans less sensitive to pricing compression in wholesale cannabis markets, but it also means recovery is harder if a borrower defaults and the property has limited alternative use.

The company's reliance on NAV financing rather than equity issuance may reflect investor sentiment. Cannabis-focused public companies trade at discounts to NAV, and raising equity at those levels would dilute existing shareholders. Borrowing against the portfolio avoids that problem — at the cost of adding leverage and marking assets to market.

For Ares, the appeal is clear: senior secured exposure to a high-yield asset class without directly lending to cannabis operators. Ares is lending to Chicago Atlantic, a publicly traded BDC, not to the cultivators and retailers in the underlying portfolio. That removes one layer of headline risk and potentially simplifies compliance, even though the economic exposure is identical.

The cannabis industry has spent the better part of a decade waiting for federal reform that never quite arrives. The Safe Banking Act has been introduced in multiple sessions of Congress. The Biden administration moved to reschedule cannabis from Schedule I to Schedule III, a change that would reduce the tax burden on operators but wouldn't legalize the plant or open up bank access. As of April 2026, none of it has happened.

What has happened instead is market consolidation, margin compression, and a liquidity squeeze. Multi-state operators that raised billions in the SPAC boom are now refinancing at distressed rates or selling assets. Smaller operators are getting acquired or shutting down. And lenders like Chicago Atlantic are stepping in to provide rescue capital — at a price.

The result is a market where the cost of capital is inversely correlated with desperation. Well-capitalized operators with diversified state footprints can borrow at 10-12%. Single-state operators with lumpy cash flows pay 15-18%. And distressed borrowers pay whatever the lender asks.

Chicago Atlantic's $300 million facility suggests the company expects deal flow to remain strong — not because the industry is thriving, but because operators need capital and have nowhere else to turn. That's a durable tailwind as long as federal reform stays theoretical. If reform actually happens, the market changes overnight: banks enter, rates compress, and specialty lenders lose their moat.

The company is betting that won't happen soon enough to matter. And if it does, the portfolio will have been refinanced at lower rates and the NAV facility paid down with proceeds.

The downside scenario for Chicago Atlantic isn't loan defaults — the loans are senior secured and backed by hard assets. The risk is that the assets aren't worth what the appraisals say they are. A 100,000-square-foot cultivation facility in rural Oklahoma is worth something. But if the borrower defaults and the property can't be sold to another cannabis operator, what's it worth as a greenhouse? As a warehouse? As dirt?

NAV facilities are marked to the appraised value of collateral, not the face value of loans. If appraisals fall, the advance rate on the Ares facility resets and Chicago Atlantic has to either repay a portion of the line or pledge additional collateral. That's a liquidity event in a worst-case scenario — and a problem that compounds if multiple borrowers default at once.

Chicago Atlantic's deal is part of a broader shift in how public and private credit vehicles finance themselves. NAV facilities, once the exclusive domain of private equity funds, are now being used by BDCs, interval funds, and even some hedge funds. The appeal is leverage without dilution. The risk is mark-to-market collateral calls.

In private equity, NAV loans are typically used to fund follow-on investments, pay management fees, or return capital to LPs while keeping portfolio companies in the fund. In credit vehicles like Chicago Atlantic, the use case is different: deploy more capital into new loans without raising equity at a discount to NAV.

The shift reflects two things. First, institutional appetite for yield has pushed investors into alternative credit, and managers need leverage to generate the returns LPs expect. Second, public market valuations for specialty finance companies are often depressed, making equity raises unattractive. NAV financing solves both problems — at the cost of adding complexity and mark-to-market risk.

Ares, which manages $450 billion across credit, private equity, and real estate, has become a major provider of NAV facilities. The firm has lent against portfolios of direct loans, real estate assets, and even venture capital stakes. Chicago Atlantic is a small deal by Ares standards, but it's emblematic of the broader trend: traditional corporate debt is expensive, equity is dilutive, so asset-based lending fills the gap.

BDCs were created in 1980 to provide capital to small and mid-sized businesses that couldn't access public markets. They get tax benefits in exchange for distributing most of their income as dividends. They're regulated by the SEC and subject to leverage limits. But they're not banks — they don't take deposits, they're not FDIC-insured, and they don't have access to the Federal Reserve's discount window.

NAV financing muddies that distinction. By borrowing against their portfolios and using the proceeds to make more loans, BDCs are effectively creating leverage on leverage. That's not inherently dangerous, but it does concentrate risk. If the underlying loans perform, everyone wins. If they don't, losses cascade.

Ten years ago, cannabis lending was family offices and hard money lenders charging 20% with no appraisal. Five years ago, it was private credit funds experimenting with the sector. Today, it's public BDCs with NAV facilities from blue-chip asset managers. That's a form of institutionalization — even if it's institutionalization at arm's length.

Ares isn't lending directly to cannabis operators. It's lending to a lender that lends to cannabis operators. That extra layer of indirection makes the financing palatable to institutional capital that still can't — or won't — touch the plant directly. It's the same dynamic that allowed Cowen and Canaccord to underwrite cannabis SPACs while Goldman and Morgan Stanley sat out.

The trajectory is toward normalcy, but slowly. Cannabis operators still can't get SBA loans or revolvers from JPMorgan. But they can borrow from a BDC that borrowed from Ares. That's progress, in a convoluted sort of way.

The question is what happens when — if — federal reform arrives. Does the capital stack collapse as banks flood in with cheaper money? Or does the sector stay bifurcated, with prime borrowers going to banks and riskier operators staying with specialty lenders? Chicago Atlantic is betting on the latter.

If you're a cannabis operator looking for real estate financing in 2026, Chicago Atlantic's $300 million facility is good news. It means one of the largest lenders in the space has fresh capital and is open for business. It also means competition for deals may ease slightly, since the company can now fund larger transactions without syndicating.

But it doesn't mean capital is getting cheaper. Chicago Atlantic is a for-profit lender with shareholders to answer to. The NAV facility from Ares has a cost, and that cost gets passed through to borrowers. If the company was lending at 12% before, it's still lending at 12% now — possibly more if market conditions have worsened since the last deal.

What it does mean is that the market for cannabis real estate credit is deep enough to support structured leverage. That's a signal of maturity. It also means that if you're a borrower, you're now competing not just with other operators but with a lender's need to hit return targets on a leveraged portfolio. That changes the underwriting conversation.

Expect more scrutiny on property valuations, exit strategies, and alternative use cases. Expect tighter covenants. Expect lenders to ask harder questions about what happens if wholesale cannabis prices keep falling. The capital is there, but it's not patient capital — it's capital with a clock on it.

For borrowers with strong balance sheets and diversified revenue, that's manageable. For operators already on the edge, it's one more squeeze in a sector that's been squeezing for years.

Chicago Atlantic's NAV facility is either a shrewd tactical move or a sign that the cannabis credit market has reached the limits of traditional financing. The optimistic reading: management sees strong risk-adjusted returns and is using leverage to maximize deployment while the opportunity window is open. The skeptical reading: the company can't raise equity at a reasonable valuation and is borrowing against its own book to keep the machine running.

Both can be true. The cannabis industry is stuck in a strange equilibrium where federal reform is always two years away, state markets are maturing but still fragmented, and capital is scarce but not absent. That creates opportunity for lenders willing to take on complexity and regulatory risk. It also creates tail risk if the equilibrium breaks.

What happens if a major multi-state operator defaults? What happens if a state pulls licenses or bans vertical integration? What happens if the IRS starts enforcing 280E more aggressively? These aren't hypotheticals — they're scenarios that lenders price into spreads but can't fully hedge.

Chicago Atlantic is betting that those risks are manageable and that the returns justify the exposure. The $300 million from Ares suggests at least one sophisticated institutional investor agrees. But NAV facilities are mark-to-market instruments. If the bet goes wrong, the feedback loop is fast.